Treatment of Sleep Disordered Breathing in Adults and Children

Effective Date: January 1, 2024
Next Review Date: July 2024
Policy Number: SLP022022
Clinical Guideline: Treatment of Sleep Disordered Breathing in Adults and Children

This is a guideline only. The guideline does not represent medical advice. Medical decisions are the responsibility of the member and the attending physician. Benefits are determined by the health plan and employer group contract and eligibility of the subscriber at the time services were rendered.

For Medicare and Medicare Advantage enrollees, the coverage policies of CMS (Centers for Medicare and Medicaid Services) take precedence over Mass General Brigham’s guidelines.

POSITIVE AIRWAY PRESSURE THERAPY

Obstructive Sleep Apnea (OSA)
Treatment for obstructive sleep apnea should be coordinated by a qualified healthcare professional who works with the member to identify an appropriate treatment plan. It is expected that members receive lifestyle counseling, where applicable, for treatment of underlying factors contributing to the obstructive sleep apnea symptoms. Educational interventions at the initiation of PAP therapy a considered a best practice.

Continuous Positive Airway Pressure (CPAP) and Auto titrating Positive Airway Pressure (APAP) (E0601)
At an effective pressure level is a standard treatment for obstructive sleep apnea. The appropriate pressure setting for CPAP may be determined during an attended facility titration study. A sleep technologist manually adjusts the CPAP pressure to determine the optimal therapeutic pressure setting, which is then programmed into the CPAP so that a fixed airflow pressure is consistently administered during therapy. Auto-Titrating Positive Airway Pressure (APAP) devices vary the pressure during treatment, based on measurements of the patient’s physiologic response, such as airflow, pressure fluctuations or measures of airway resistance. Auto-adjusting PAP devices apply constant pressure, or bi-level pressure changes, as in bi-level PAP.

For members without significant comorbidities (e.g., CHF, COPD, central or treatment- emergent sleep apnea, obesity hypoventilation syndrome, or other concomitant sleep disorders) APAP devices may be initiated in the home setting and used in the self- adjusting mode in lieu of an attended facility titration for treatment of patients with obstructive sleep apnea.

Clinical practice standards advise that patients being treated with fixed CPAP or APAP (E0601) therapy have close clinical follow up to determine the effectiveness of treatment, especially during the initial weeks of therapy. If obstructive sleep apnea symptoms are not resolved effectively with CPAP or APAP, a clinical reevaluation may be medically necessary.

Bi-level Positive Airway Pressure WITHOUT back-up rate (E0470)
A bi-level positive airway pressure device is a respiratory assist device that is able to deliver separate expiratory and inspiratory positive airway pressures for assisted ventilation and may improve results and comfort for some members with OSA as well as other sleep disordered and respiratory conditions.

Bi-level Positive Airway Pressure WITH back-up rate (E0471)
A bi-level positive airway pressure device with a back-up rate delivers adjustable, variable levels (within a single respiratory cycle) of positive air pressure by way of tubing and a noninvasive interface to assist spontaneous respiratory efforts and provide a device-delivered breath if a spontaneous breath is not sensed in a pre-specified time period.

I. Positive Airway Pressure for the Treatment of OSA

CPAP or APAP therapy with or without a humidifier (E0561 or E0562) is considered medically necessary for an initial period of 90 days for adult members who are diagnosed with obstructive sleep apnea, as evidenced by a positive facility-based polysomnogram PSG, or a positive Home Sleep Apnea HSAT, as defined by either of the following criteria:

A. Apnea/Hypopnea (AHI), Respiratory Disturbance Index (RDI) or Respiratory Event Index (REI) greater than or equal to 15 events per hour, in adult members with symptomatic or asymptomatic OSA.

B. AHI, RDI, or REI greater than or equal to 5 and less than 15 events per hour and at least one of the following is met:
   1. History of stroke
   2. Hypertension
   3. Ischemic heart disease
   4. Symptoms of impaired cognition, mood disorders or insomnia
   5. Evidence suggestive of excessive daytime sleepiness

CPAP or APAP with or without a humidifier (E0561 or E0562) for an initial 90-day period is considered medically necessary for the treatment of OSA in a child when ALL of the following criteria are met:

1. OSA diagnosis established by diagnostic sleep test
2. Child weighs 30 kilograms (66 pounds) or more
3. Adenotonsillectomy has been unsuccessful or is contraindicated, or when definitive surgery is indicated but must await complete dental and facial development

Treatment of snoring alone, without obstructive sleep apnea, is not considered medically necessary

Bi-level therapy without a backup rate feature (E0470) is considered medically necessary for an initial period of 90 days for the treatment of obstructive sleep apnea when:

A. CPAP has been tried and proven ineffective or is not tolerated as documented by a qualified health professional.

II. Positive Airway Pressure for Treatment of Other Sleep Disordered Breathing Conditions

Bi-level therapy with or without a backup rate feature (E0470/E0471*) is considered medically necessary for an initial period of 90 days for members with clinical disorder groups (other than OSA) characterized as one of the following (see specific criteria for each specific disorder) conditions:

1. Restrictive thoracic disorder
2. Severe COPD with evidence of hypercapnia,
3. Central sleep apnea (CSA) or treatment-emergent central sleep apnea.
4. Hypoventilation syndrome

*NOTE: Most titrations are started with Bi-level without a backup rate; the backup rate is added if incomplete resolution of the sleep disordered breathing. Most often, this is due to persistent CSA or in patients with insufficient (variable) respiratory pattern i.e. patients with neuromuscular diagnoses.

Restrictive Thoracic Disorders
An E0470 or E0471 device is considered medically necessary when all of the following criteria are met:

A. One of the following:
   1. An arterial blood gas PaCO2, done while awake and breathing the member’s usual FI02 is greater than or equal to 45 mm Hg;
   2. Sleep oximetry demonstrates oxygen saturation less than or equal to 88% for at least five continuous minutes, done while breathing the member’s usual FI02;
   3. For a progressive neuromuscular disease (only), maximal inspiratory pressure is less than 60 cm H2O or forced vital capacity (FVC) is less than 50% predicted;

B. There is documentation that chronic obstructive pulmonary disease does not contribute significantly to the member’s pulmonary limitation.

Severe COPD
An E0470 device is considered medically necessary when all of the following criteria are met:

A. An arterial blood gas PaCO2, done while awake and breathing the member’s usual FI02, is greater than or equal to 52 mm Hg;

B. Sleep oximetry demonstrates oxygen saturation less than or equal to 88% for at least five continuous minutes, done while breathing oxygen at 2 LPM or the member’s usual FI02 (whichever is higher);

C. Prior to initiating therapy, Obstructive Sleep Apnea (OSA) and treatment with a continuous positive airway pressure device (CPAP) has been tried and failed, not tolerated or considered and ruled out.

An E0471 device is considered medically necessary for a member for either of the following A or B:

A. For members with COPD who qualified for an E0470 device, an E0471 started any time after a period of initial use of an E0470 device is considered medically necessary when both criteria 1 and 2 are met.

1. An arterial blood gas PaCO2, done while awake and breathing the member’s prescribed FI02, shows that the member’s PaCO2 greater than 52 or pre ABG PaCO2 increase equal to or greater than 7 mm HG compared to the original result from criterion 1 (above).
2. A facility-based PSG demonstrates oxygen saturation less than or equal to 88% for greater than or equal to a cumulative 5 minutes of nocturnal recording time (minimum recording time of 2 hours) while using an E0470 device that is not caused by obstructive upper airway events – i.e., AHI less than 5.

B. Member’s with COPD who are started on bi-level positive pressure (E0470, E0471) at discharge from hospitalization, can continue for up to 3 months to provide time to stabilize and/or complete re-evaluation

Central Sleep Apnea or Treatment-Emergent Central Sleep Apnea

An E0470 or E0471 device is considered medically necessary when:

A. Prior to initiating therapy, a complete facility-based, attended polysomnogram must be performed documenting ALL of the following:

1. The diagnosis of central sleep apnea (CSA) or treatment-emergent central sleep apnea;

2. The ruling out of CPAP as effective therapy if either CSA or OSA is a component of the initially observed sleep-associated hypoventilation;

3. Significant improvement of the sleep-associated hypoventilation with the use of a bi-level therapy on the settings that will be prescribed for initial use at home, while breathing the member’s usual FIO2.

**NOTE:** Adaptive Servo-Ventilation, auto SV/Bopp and auto SV advanced devices (E0471) should not be used in individuals with symptomatic chronic congestive heart failure (CHF) with reduced ejection fraction (LVEF less than or equal to 45%). Resumed Ltd® identified a significant increase in the risk of cardiovascular death in individuals with symptomatic, chronic heart failure (NYHA II – IV) with reduced ejection fraction (LVEF less than or equal to 45%) and moderate to severe predominant central sleep apnea (AHI greater than or equal to 15, CAHI/AHI greater than or equal to 50% and CAI greater than or equal to 10). Philips Respironics® issued the same warning for at-risk individuals using Bopp autoSV/Bopp auto SV Advanced devices. In individuals with LVEF greater than 45% or mild CHF-related central sleep apnea, ASV may be used as an option for treatment, at the clinical discretion of the prescribing qualified healthcare professional

Hypoventilation Syndrome

An E0470 device is considered medically necessary when both criteria A and B and either criterion C or D are met.

A. An initial arterial blood gas PaCO2, done while awake and breathing the member’s prescribed FIO2, is greater than or equal to 45 mm Hg

B. Spirometry shows an FEV1/FVC greater than or equal to 70%. (Refer to SEVERE COPD (above) for information about device coverage for members with FEV1/FVC less than 70 %.)

C. An arterial blood gas PaCO2, done during sleep or immediately upon awakening, and breathing the member’s prescribed FIO2, shows the member’s PaCO2 worsened greater than or equal to 7 mm HG compared to the original result in criterion A (above).
D. A facility-based PSG or HST while on CPAP and prescribed FiO2 demonstrates oxygen saturation less than or equal to 88% for greater than or equal to 5 minutes of nocturnal recording time (minimum recording time of 2 hours) that is not caused by obstructive upper airway events – i.e., AHI less than 5.

If the above criteria are not met, E0470 and related accessories will be considered not medically necessary.

An E0471 device is considered medically necessary when both criteria A, B and either criterion C or D are met:

A. A covered E0470 device is being used and found to be ineffective.

B. Spirometry shows an FEV1/FVC greater than or equal to 70%. (Refer to SEVERE COPD (above) for information about device coverage for members with FEV1/FVC less than 70%).

C. An arterial blood gas PaCO2, done while awake, and breathing the member’s prescribed FiO2, shows that the member’s PaCO2 worsens greater than or equal to 7 mm HG compared to the ABG result performed to qualify the member for the E0470 device (criterion A under E0470).

D. A facility-based PSG or HST while using E0470 and prescribed FiO2 demonstrates oxygen saturation less than or equal 88% for greater than or equal to 5 minutes of nocturnal recording time (minimum recording time of 2 hours) that is not caused by obstructive upper airway events – i.e., AHI less than 5 while using an E0470 device.

If the criteria above are not met, an E0471 device is considered not medically necessary

Positive Airway Pressure Therapy Adherence

Treatment of obstructive sleep apnea with Positive Airway Pressure Therapy (PAP) therapy is dependent on patient adherence to the prescribed treatment. Close follow-up by a qualified healthcare professional and review of objective adherence data is recommended during PAP treatment to assure that the patient is prescribed the appropriate therapeutic pressure and is fit with an appropriate interface to encourage maximum use.

The first 90 days of PAP therapy are frequently considered an important trial period to assess patients’ ability to comply with the treatment, and to evaluate the overall efficacy of PAP in resolving and/or minimizing the obstructive sleep apnea symptoms. If PAP is considered inadequate, based on objective adherence monitoring and symptom evaluation, efforts should be implemented to improve PAP adherence, or alternative therapies should be considered.

When PAP therapy is not successful, as evidenced by lack of patient adherence to prescribed therapy, and/or inadequate clinical response to therapy, the ordering qualified healthcare professional should discuss other treatment options with the patient.

CONTINUED COVERAGE BEYOND THE FIRST THREE MONTHS (90 days) OF THERAPY
CPAP/APAP (E0601) Devices and Bi-level Device (E0470) for the treatment of Obstructive Sleep Apnea

Continued coverage of a PAP device beyond the first three months (90 days) of therapy requires that, no sooner than the 31st day but no later than the 91st day after initiating therapy, there must be documentation the member is adhering to PAP therapy.

A. Objective evidence of adherence use of PAP therapy for the diagnosis of OSA is defined as:

1. Use of PAP ≥ 4 hours per night on 70% of nights during a consecutive thirty (30) day period anytime during the first three (3) months of initial usage.

Bi-level device (E0470 AND E0471) for the treatment of diagnoses other than Obstructive Sleep Apnea require the following documentation:

A. Signed and dated statement completed by the treating practitioner no sooner than 61 days after initiating use of the device, declaring that the member is compliantly using the device (an average of 4 hours per 24 hour period) and that the member is benefiting from its use.

If the above criterion is not met, continued coverage of a PAP device and related accessories is considered not medically necessary.

In cases of lack of adherence, coverage of the PAP equipment and supplies may be discontinued based upon the health plan’s coverage policy.

PAP REPLACEMENT

A replacement of a PAP device/supplies is considered medically necessary with a prescription from a qualified health professional. Confirmation must exist that the device is:

- nonfunctioning and out of warranty, or
- the device is greater than five years old

Documentation may come from the physician or rendering provider.

NOTE: If above criteria are met and a previous diagnostic test is not available, physician attestation supporting a diagnosis of OSA will be accepted to support replacement device.

Other

Duplicate equipment is considered a convenience (e.g., travel PAP) and is not considered medically necessary. Replacement of a PAP device for the purposes of upgrading technology is not considered medically necessary.

Accessories and Supplies

The following accessories and supplies are considered medically necessary for members who meet criteria for PAP therapy. Guidelines for use and frequency of replacement should be based on industry standard practice and medical necessity, and are acceptable to most patients with normal usage. (See section titled PAP Supply Guidance)
• Chinstrap
• Disposable and/or non-disposable filters
• Nasal mask or oronasal mask (full face mask)
• Headgear
• Humidifier – heated or non-heated
• Replacement cushion or nasal pillows for nasal application device
• Replacement interface for oronasal mask
• Tubing - heated or non-heated

PAP Cleaning Machines or devices are considered items of convenience and not covered. In addition, the FDA has not evaluated the safety and effectiveness of ozone gas or UV light products claiming to clean, sanitize or disinfect CPAP machines and accessories in the home or healthcare setting. Additionally, both ozone and UV light cleaning products (including the Philips UV Light Sanitizer Box) are not currently approved cleaning methods for Philips Respironics devices or masks.

---

**Other non-surgical therapies**

PAP therapy remains the “gold standard” for treatment for obstructive sleep apnea. However, other nonsurgical therapies may be considered when PAP cannot be tolerated or when an alternate therapeutic option is considered medically appropriate.

Coverage for oral appliances may be subject to the terms, conditions and limitations of the applicable benefit plan’s External Prosthetic Appliances and Devices (EPA) or Durable Medical Equipment (DME) benefit and schedule of copayments.

---

Over-the-counter (OTC) oral appliances obtained without a prescription are not considered medically necessary.

**Experimental and Investigational**

The following **OSA therapies** are considered experimental and investigational or unproven.

• Sleep Strip
• Oral device/Appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, (e.g., eXite OSA)
• Oral pressure therapy (e.g., Winx® Sleep Therapy System)
• Provent™ Professional Sleep Apnea Therapy Device
• Atrial overdrive pacing
• Cautery-assisted palatal stiffening operation (CAPSO)
• Electrical devices (e.g., Night Shift™ Sleep Positioner, Night Balance) as therapy for positional obstructive sleep apnea
• Electrosleep therapy
• Injection Snoreplasty
• Laser-assisted uvulopalatoplasty (LAUP)
• Over-the-counter, non-customized mandibular appliances
• Pillar™ Palatal Implant System
• Radiofrequency volumetric tissue reduction (RFVTR) of the soft palate, uvula, or tongue base (e.g., Coblation®, Somnoplasty®)
• Tongue-base suspension (e.g., AIRVance System)
• Transpalatal advancement pharyngoplasty
• Diaphragmatic-Phrenic Nerve Stimulation for the treatment of CSA

**REIMBURSEMENT INFORMATION**

**NOTE:** Services in excess of what is documented in this policy are subject to medical review of documentation that supports medical necessity. The following information is required to support medical necessity: physician history and physical, physician procedure note, treatment plan, plan of treatment, and sleep study results (PSG or HSAT as appropriate)

**PAP SUPPLY GUIDANCE**

The following supply table represents the usual maximum of supplies expected to be reasonable and necessary.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>A4604</td>
<td>TUBING WITH INTEGRATED HEATING ELEMENT FOR USE WITH POSITIVE AIRWAY PRESSURE DEVICE</td>
<td>1 per 3 months</td>
</tr>
<tr>
<td>A7027</td>
<td>COMBINATION ORAL/NASAL MASK, USED WITH CONTINUOUS POSITIVE AIRWAY PRESSURE DEVICE, EACH</td>
<td>1 per 3 months</td>
</tr>
<tr>
<td>A7028</td>
<td>ORAL CUSHION FOR COMBINATION ORAL/NASAL MASK, REPLACEMENT ONLY, EACH</td>
<td>2 per 1 month</td>
</tr>
<tr>
<td>A7029</td>
<td>NASAL PILLOWS FOR COMBINATION ORAL/NASAL MASK, REPLACEMENT ONLY, PAIR</td>
<td>2 per 1 month</td>
</tr>
<tr>
<td>A7030</td>
<td>FULL FACE MASK USED WITH POSITIVE AIRWAY PRESSURE DEVICE, EACH</td>
<td>1 per 3 months</td>
</tr>
<tr>
<td>A7031</td>
<td>FACE MASK INTERFACE, REPLACEMENT FOR FULL FACE MASK, EACH</td>
<td>1 per 1 month</td>
</tr>
<tr>
<td>A7032</td>
<td>CUSHION FOR USE ON NASAL MASK INTERFACE, REPLACEMENT ONLY, EACH</td>
<td>2 per 1 month</td>
</tr>
<tr>
<td>A7033</td>
<td>PILLOW FOR USE ON NASAL CANNULA TYPE INTERFACE, REPLACEMENT ONLY, PAIR</td>
<td>2 per 1 month</td>
</tr>
<tr>
<td>A7034</td>
<td>NASAL INTERFACE (MASK OR CANNULA TYPE) USED WITH POSITIVE AIRWAY PRESSURE DEVICE, WITH OR WITHOUT HEAD STRAP</td>
<td>1 per 3 months</td>
</tr>
<tr>
<td>A7035</td>
<td>HEADGEAR USED WITH POSITIVE AIRWAY PRESSURE DEVICE</td>
<td>1 per 6 months</td>
</tr>
<tr>
<td>A7036</td>
<td>CHINSTRAP USED WITH POSITIVE AIRWAY PRESSURE DEVICE</td>
<td>1 per 6 months</td>
</tr>
<tr>
<td>A7037</td>
<td>TUBING USED WITH POSITIVE AIRWAY PRESSURE DEVICE</td>
<td>1 per 3 months</td>
</tr>
<tr>
<td>A7038</td>
<td>FILTER, DISPOSABLE, USED WITH POSITIVE AIRWAY PRESSURE DEVICE</td>
<td>2 per 1 month</td>
</tr>
<tr>
<td>A7039</td>
<td>FILTER, NON DISPOSABLE, USED WITH POSITIVE AIRWAY PRESSURE DEVICE</td>
<td>1 per 6 months</td>
</tr>
<tr>
<td>A7046</td>
<td>WATER CHAMBER FOR HUMIDIFIER, USED WITH POSITIVE AIRWAY PRESSURE DEVICE, REPLACEMENT, EACH</td>
<td>1 per 6 months</td>
</tr>
</tbody>
</table>
**HCPCS CODING:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A4604</td>
<td>Tubing with integrated heating element for use with positive airway pressure device</td>
</tr>
<tr>
<td>A7027</td>
<td>Combination oral/nasal mask, used with continuous positive airway pressure device, each</td>
</tr>
<tr>
<td>A7028</td>
<td>Oral cushion for combination oral/nasal mask, replacement only, each</td>
</tr>
<tr>
<td>A7029</td>
<td>Nasal pillows for combination oral/nasal mask, replacement only, pair</td>
</tr>
<tr>
<td>A7030</td>
<td>Full face mask used with positive airway pressure device, each</td>
</tr>
<tr>
<td>A7031</td>
<td>Face mask interface, replacement for full face mask, each</td>
</tr>
<tr>
<td>A7032</td>
<td>Cushion for use on nasal mask interface, replacement only, each</td>
</tr>
<tr>
<td>A7033</td>
<td>Pillow for use on nasal cannula type interface, replacement only, pair</td>
</tr>
<tr>
<td>A7034</td>
<td>Nasal interface (mask of cannula type) used with positive airway pressure device, with or without head strap</td>
</tr>
<tr>
<td>A7035</td>
<td>Headgear used with positive airway pressure device</td>
</tr>
<tr>
<td>A7036</td>
<td>Chinstrap used with positive airway pressure device</td>
</tr>
<tr>
<td>A7037</td>
<td>Tubing used with positive airway pressure device</td>
</tr>
<tr>
<td>A7038</td>
<td>Filter, disposable, used with positive airway pressure device</td>
</tr>
<tr>
<td>A7039</td>
<td>Filter, nondisposable, used with positive airway pressure device</td>
</tr>
<tr>
<td>A7044</td>
<td>Oral interface used with positive airway pressure device, each</td>
</tr>
<tr>
<td>A7045</td>
<td>Exhalation port with or without swivel used with accessories for positive airway devices, replacement only</td>
</tr>
<tr>
<td>A7046</td>
<td>Water chamber for humidifier, used with positive airway pressure device, replacement, each</td>
</tr>
<tr>
<td>E0561</td>
<td>Humidifier, non-heated, used with positive airway pressure device</td>
</tr>
<tr>
<td>E0562</td>
<td>Humidifier, heated, used with positive airway pressure device</td>
</tr>
<tr>
<td>E0470</td>
<td>Respiratory assist device, bi-level pressure capability, without backup rate feature, used with noninvasive interface, e.g., nasal or facial mask (intermittent assist device with continuous positive airway pressure device)</td>
</tr>
<tr>
<td>E0471</td>
<td>Respiratory assist device, bi-level pressure capability, with backup rate feature, used with noninvasive interface, e.g., nasal or facial mask (intermittent assist device with continuous positive airway pressure device) [describes adaptive servo ventilation]</td>
</tr>
<tr>
<td>E0601</td>
<td>CPAP (continuous positive airway pressure) device (also used for reporting APAP)</td>
</tr>
</tbody>
</table>

**Medicare Advantage and Dual-Eligible Special Needs Plan (DSNP) Coverage**

The NCD Sleep Testing for Obstructive Sleep Apnea (OSA) 240.4.1 policy does not delineate which diagnostic test is most appropriate for management of clinical signs or symptoms of OSA; that is, it does not specify criteria for determining when a home sleep test or an in-lab Polysomnography (PSG) test is most appropriate. The NCD states that either PSG or HSAT will be covered when used to aid the diagnosis of OSA in beneficiaries who have clinical signs and symptoms indicative of OSA.

The following National and Local Coverage Determinations (NCD/LCD) are used to determine medical necessity for patients enrolled in a Medicare Advantage or DSNP plan:

- Continuous Positive Airway Pressure (CPAP) 240.4 (cms.gov)
Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea L33718
Respiratory Assist Devices L33800 (cgsmedicare.com).

Medicare Advantage (MA) plans will consult the Medicare Benefit Policy Manual, Medicare Program Integrity Manual, and similar CMS guidance materials. Using these resources will ensure that MA plans are covering items and services for which benefits are available under Part A and Part B for their enrollees and minimize the number of potential situations where Traditional Medicare coverage policies have insufficient detail such that an MA plan must develop its own internal coverage criteria.

Managed Medicaid Coverage:
There is no published medical policy for patients enrolled in a Massachusetts Managed Medicaid plan. The medical policy above applicable to patients enrolled in a commercial plan also applies to patients enrolled in a Managed Medicaid plan.

DEFINITIONS

Apnea: temporary cessation of breathing and, therefore, of the body's intake of oxygen and release of carbon dioxide; cessation of airflow for 10 seconds or more

Apnea-Hypopnea Index (AHI): the total number of apneas and hypopneas per hour of sleep. AHI is an index of severity of obstructive sleep apnea. AHI is calculated by dividing the number of apneas plus the number of hypopneas by the number of hours of sleep.

If the AHI is calculated based on less than 2 hours of continuous recorded sleep, the total number of recorded events used to calculate the AHI must be at least the number of events that would have been required in a 2-hour period (i.e., greater than or equal to 10 events).

Central Sleep Apnea (CSA): the repeated cessation of breathing caused by the temporary signal loss from the brain sent to the breathing muscles. CSA is most often seen in patients with neurologic disorders, congestive heart failure and in patients who take certain medications (e.g., opiates, benzodiazepines).

Hypersomnolence: excessive sleepiness during the typical period of wakefulness.

Hypopnea: an abnormal respiratory event lasting at least ten seconds with at least 30% reduction in thoracoabdominal movement or airflow as compared to baseline, and with at least a 4% oxygen desaturation, or a ≥ 3% oxygen desaturation from pre-event baseline and/or the event is associated with an arousal.

Nocturnal: pertaining to, occurring at, or active at night.

O2 Saturation: percentage of oxygen carried by the blood.

Obstructive Sleep Apnea (OSA): characterized by repetitive apneas and/or hypopneas during sleep, caused by complete or partial collapse of pharyngeal airway during sleep. In adults, an apnea/hypopnea index (AHI) greater than or equal to 5 but less than 15 is considered mild OSA. AHI greater than or equal to 15 but less than 30 is considered moderate OSA. AHI greater than or equal to 30 is considered severe OSA. In pediatric patients, an AHI greater than or equal to 1 is considered abnormal.
Respiratory Disturbance Index (RDI): number of apneas + hypopneas + respiratory-related events during the sleep test divided by the total number of hours slept.

Respiratory-Event Index (REI): a measurement of sleep disordered breathing on home sleep apnea testing defined as number of apneas + hypopneas during the sleep test divided by the total sleep or recording time reported in hours.

Treatment-Emergent Central Sleep Apnea is a form of central sleep apnea specifically identified by the persistence or emergence of central apneas and/or hypopneas upon exposure to CPAP, bi-level therapy, or APAP, when obstructive events have disappeared. These members have predominately obstructive or mixed apneas during the diagnostic sleep study occurring at greater than or equal to 5 times per hour. With use of a CPAP, bi-level therapy, or APAP, they show a pattern of central apneas and/or central hypopneas that meets the definition of CSA described above.

References


5. Centers for Medicare and Medicaid Services National Coverage Decision for Sleep Testing for Obstructive Sleep Apnea (OSA) 240.4.1 Published 8/10/2009.

6. Centers for Medicare and Medicaid Services LCD for Respiratory Assistive Devices (L33800) 8/8/2021


8. Local Coverage Determination (LCD) L38398: Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea (L38387) effective 4/1/2020, National Government Services:


13. Kushida CA; Chediak A; Berry RB; Brown LK; Gozal D; Iber C; Parthasarathy S; Quan SF; Rowley JA; Clinical Guidelines for the Manual Titration of Positive Airway Pressure in Patients with Obstructive Sleep Apnea. Positive Airway Pressure Titration Task Force of the American Academy of Sleep Medicine. Journal of Clinical Sleep Medicine, Vol. 4, No. 2, 2008


21. Centers for Medicare and Medicaid Services LCD for Continuous Positive Airway Pressure System (CPAP) (L33718) Revision Effective Date 1/1/2020;


27. Resmed Ltd, Urgent: Field Safety Notice, Increased Risk of Cardiovascular Death with Adaptive ServoVentilation (ASV) Therapy for Patients with Symptomatic Chronic Heart Failure with Reduced Ejection Fraction; May 13, 2015.


31. Michael R. Littner MD1; Clete Kushida MD, PhD2; Merrill Wise MD3; David G. Davila, MD4; TimothyMorgenthaler MD5; Teofilo Lee-Chiong MD6; Max Hirshkowitz PhD7; Daniel L. Loube MD8; Dennis Bailey DDS9; Richard B. Berry MD10; Sheldon Kapen MD11; Milton Kramer MD1. Practice Parameters for Clinical Use of the Multiple Sleep Latency Test and the Maintenance of Wakefulness Test an American Academy of Sleep Medicine Report Standards of Practice Committee of the American Academy of Sleep Medicine

32. R. Nisha Aurora, MD, MHS1; Sabin R. Bista, MD2; Kenneth R. Casey, MD, MPH3; Susmita Chowdhuri, MD4; David A. Kristo, MD5; Jorge M. Mallea, MD6; Kannan Ramar, MD7; James A. Rowley, MD8; Rochelle S. Zak, MD9; Jonathan L. Heald, Journal of Clinical Sleep Medicine, Vol. 12, No. 5, 2016. Updated Adaptive Servo-Ventilation Recommendations for the 2012 AASM Guideline: “The Treatment of Central Sleep Apnea Syndromes in Adults: Practice Parameters with an Evidence-Based Literature Review and Meta- Analyses”


35. Vishesh K. Kapur, MD, MPH; Dennis H. Auckley, MD; Susmita Chowdhuri, MD; David C. Kuhlmann, MD, Reena Mehra, MD, MS; Kannan Ramar, MBBS, MD; Christopher G. Harrod, MS Clinical Practice
47. Yancy, Clyde W. MD, MSC, MACC, Chair, James L. Januzzi, JR, MD, FACC, Vice Chair 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction


49. Michelle S. King, MD, Melissa S. Xanthopoulos, PhD, and Carole L. Marcus, MBBCh, Improving Positive Airway Pressure Adherence in Children, Sleep Med Clin. 2014 June 1; 9(2): 219–234. doi:10.1016/j.jsmc.2014.02.003 Sleep Center, The Children’s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, 34th and Civic Center Boulevard, Philadelphia, PA 19104, USA


54. Chatburn RL. Which ventilators and modes can be used to deliver noninvasive ventilation? Respir Care. 2009; 54(1):85-101.


56. Local Coverage Determination (LCD): Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea (L38387) effective 4/1/2020, National Government Services:

57. Local Coverage Determination (LCD): Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea (L38385) effective 3/15/2020, Novitas Solutions

58. Local Coverage Determination (LCD): Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea (L38398) effective 3/15/2020, First Coast Options,

59. Local Coverage Determination (LCD): Respiratory Assist Devices (L33800), 08/08/2021

60. Amanda Piper, PhD, Brendon Yee, MBChB, PhD, Clinical manifestations and diagnosis of obesity hypoventilation syndrome, Aug 22, 2019.


63. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016 US Department of Health and Human Services for Disease Control and Prevention, MMWR / March 15, 2016 / Vol. 65


65. Vishesh K. Kapur, MD, Dennis H. Auckley, MD; Susmita Chowdhuri, MD; David C. Kuhlmann, MD; Reena Mehra, MD, MS; Kanna Ramar, MBBS, MD; Christopher G. Harrod, MS Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline (page 490)


69. Technical Report: Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome Michael S. Schechter, Section on Pediatric Pulmonology, Subcommittee on Obstructive Sleep Apnea Syndrome Pediatrics Apr 2002, 109 (4) e69;


71. Merrill S. Wise, MD1; Cynthia D. Nichols, PhD2; Madeleine M., et al, Respiratory Indications for Polysomnography in Children: An Evidence-Based Review, SLEEP, Vol. 34, No. 3, 2011


73. As relates just to Obesity Hypoventilation Syndrome. Evaluation and Management of OHS: An Official Am Thoracic Society Clinical Practice Guideline


GUIDELINE UPDATE INFORMATION

<table>
<thead>
<tr>
<th>Date</th>
<th>Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/19/2013</td>
<td>New coverage guideline</td>
</tr>
<tr>
<td>5/22/2015</td>
<td>Scheduled review. Adherence criteria, criteria related to Adaptive Servo Ventilation and definitions added. Experimental/Investigational diagnostic tests updated: Actigraphy used alone, and use of Acoustic pharyngometry, or SNAP testing with fewer than three channels. Guideline reformatted, references updated</td>
</tr>
<tr>
<td>5/25/2016</td>
<td>Updated definitions of comorbid conditions and secondary sleep disorders</td>
</tr>
<tr>
<td></td>
<td>Updated ASV indications with most current recommendations</td>
</tr>
<tr>
<td></td>
<td>Expanded definition of MWT</td>
</tr>
<tr>
<td></td>
<td>Provided list of standard PAP supply replacement schedule</td>
</tr>
<tr>
<td></td>
<td>Added REI as a measurement of sleep disordered breathing</td>
</tr>
<tr>
<td></td>
<td>Updated oxygen saturation requirements for PAP titration (CPT 95811)</td>
</tr>
<tr>
<td></td>
<td>Extensive reformatting changes</td>
</tr>
<tr>
<td>3/28/2017</td>
<td>Sleep disorders without suspected OSA identified as criteria for in- facility testing</td>
</tr>
<tr>
<td>6/21/2017</td>
<td>Scheduled review: added PAP replacement language, in-facility diagnostic testing for sleep disorders not associated with OSA</td>
</tr>
<tr>
<td>8/9/2018</td>
<td>Scheduled review: describe snoring as habitual vs. disruptive as suggestive evidence of sleep disordered breathing; inclusion of chronic opioid use as a comorbid condition; expand measurement of compliance over a 24 hour period.</td>
</tr>
<tr>
<td>Date</td>
<td>Event Description</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>6/8/2020</td>
<td><strong>Scheduled Review:</strong> &lt;br&gt; <strong>Sleep Testing</strong>  &lt;br&gt; Witnessed apnea as standalone risk condition for OSA  &lt;br&gt; Updated LVEF from 45% to 40% for moderate to severe CHF  &lt;br&gt; OHS moved from sleep disordered breathing to comorbid condition list  &lt;br&gt; Align definition of PAP compliance with CMS  &lt;br&gt; Increase timeframe from 90 days to 1 year for allowance of HSAT  &lt;br&gt; Include implantation of hypoglossal nerve stimulator for testing reassessment of efficacy of device</td>
</tr>
<tr>
<td>5/24/2021</td>
<td><strong>Scheduled Review:</strong> &lt;br&gt; Further defined the evidence supporting conditions requiring a lab based sleep study pertaining to:  &lt;br&gt; COPD  &lt;br&gt; Asthma  &lt;br&gt; Refractory cardiac arrhythmia  &lt;br&gt; Chronic opioid medication use  &lt;br&gt; Significant oxygen desaturation during diagnostic testing  &lt;br&gt; Update for requirements for replacement positive airway pressure devices (PAP) when broken and patient has been previously diagnosed with OSA and doing well on therapy.  &lt;br&gt; Streamline and clarify sleep study re-testing for adults and children  &lt;br&gt; Parasomnias in children</td>
</tr>
<tr>
<td>7/20/2022</td>
<td><strong>Annual Review and Update</strong>  &lt;br&gt; Added replacement after 5 years</td>
</tr>
<tr>
<td>06/20/23</td>
<td><strong>Annual Review and Update</strong>  &lt;br&gt; Updated PAP cleaning machines statement regarding ozone and UV light cleaning products  &lt;br&gt; Updated list of obstructive sleep apnea therapies list  &lt;br&gt; Added HCPCS table</td>
</tr>
</tbody>
</table>